Science Explorer Interactive view Map
Company · Taizhou · China

Jiangsu T-mab BioPharma (China)

taikang.d79.163ns.cnROR OpenAlex
World rank, 2022–2025
#19,998
of 28,054
Rank in China
#2,854
of 3,058
Research works
108
▲ 675% vs 2013–17
Citations
563
5.2 per fractional work
Top-10% rate
13.2%
record average 16.5%
Open access
33%
world 28%

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.17× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 5.30× its world share, 18 worksBiochemistry, Geneti…Immunology and Microbiology: 8.83× its world share, 6 worksImmunology and Micro…Neuroscience: 0.72× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.11× its world share, 0 worksPharmacology, Toxico…Chemical Engineering: 2.18× its world share, 0 worksChemical EngineeringChemistry: 0.71× its world share, 1 worksChemistryComputer Science: 0.04× its world share, 0 worksComputer ScienceEarth and Planetary Sciences: 0.16× its world share, 0 worksEarth and Planetary …Engineering: 0.29× its world share, 3 worksEngineeringMaterials Science: 0.54× its world share, 1 worksMaterials ScienceMathematics: 0.19× its world share, 0 worksMathematicsPhysics and Astronomy: 0.03× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.02× its world share, 0 worksHealth ProfessionsMedicine: 2.64× its world share, 33 worksMedicineVeterinary: 2.18× its world share, 0 worksVeterinaryEconomics, Econometrics and Finance: 0.02× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 8.8×. Every wedge is a field page.

Which keywords describe research at Jiangsu T-mab BioPharma (China)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Glycosylation, Monoclonal Antibodies, Cancer, Therapeutic Antibodies, Tumor Microenvironment, Antibody Engineering, Fc Receptors and Cancer Therapy.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Glycosylation9▲ 118×3 topics
  2. Monoclonal Antibodies8▲ 140×3 topics
  3. Cancer8▲ 9.0×19 topics
  4. Therapeutic Antibodies7▲ 158×2 topics
  5. Tumor Microenvironment7▲ 25×7 topics
  6. Antibody Engineering6▲ 179×1 topic
  7. Fc Receptors6▲ 179×1 topic
  8. Inflammation6▲ 4.4×21 topics
  9. Cancer Therapy5▲ 14×8 topics
  10. Immunotherapy5▲ 10.0×11 topics
  11. Cancer Immunotherapy4▲ 36×3 topics
  12. Angiogenesis3▲ 16×8 topics
  13. Immune Checkpoint Blockade3▲ 44×1 topic
  14. Monoclonal Antibody3▲ 92×2 topics
  15. PD-1 and PD-L13▲ 44×1 topic
  16. PET Imaging3▲ 27×3 topics
  17. Tumor Regression3▲ 43×2 topics
  18. Chemotherapy3▲ 6.4×9 topics
  19. Gene Therapy3▲ 22×5 topics
  20. Lymphoma3▲ 26×3 topics
  21. Transcriptional Regulation3▲ 25×5 topics
  22. Immunity2▲ 8.7×4 topics
  23. Leukemia2▲ 41×2 topics
  24. Targeted Therapy2▲ 16×5 topics
  25. CAR T Cells2▲ 45×1 topic
  26. Cell Proliferation2▲ 40×3 topics
  27. Chimeric Antigen Receptor2▲ 45×1 topic
  28. Breast Cancer2▲ 13×3 topics
  29. Immune Response2▲ 5.5×9 topics
  30. Tumor Targeting2▲ 17×3 topics
  31. Biopharmaceuticals2▲ 55×3 topics
  32. Fibroblast Activation Protein2▲ 68×1 topic
  33. Immunogenicity2▲ 69×3 topics
  34. Immunosuppression2▲ 33×1 topic
  35. Synthetic Lethality2▲ 90×2 topics
  36. HER22▲ 97×1 topic
  37. Therapeutic Targets2▲ 18×3 topics
  38. Trastuzumab2▲ 61×1 topic
  39. Proteasome Inhibitors2▲ 33×2 topics
  40. Stem Cells2▲ 9.0×3 topics

Which research topics does Jiangsu T-mab BioPharma (China) publish most on?

By volume in 2022–2025: Monoclonal and Polyclonal Antibodies Research, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research and Peptidase Inhibition and Analysis.

Monoclonal and Polyclona…6Monoclonal and Polyclonal Antibodies Research: 6 fractional worksCancer Immunotherapy and…3Cancer Immunotherapy and Biomarkers: 3 fractional worksCAR-T cell therapy resea…2CAR-T cell therapy research: 2 fractional worksPeptidase Inhibition and Analysis: 2 fractional worksHER2/EGFR in Cancer Research: 2 fractional worksViral Infectious Disease…1Viral Infectious Diseases and Gene Expression in Insects: 1 fractional worksEpigenetics and DNA Methylation: 1 fractional worksAdenosine and Purinergic Signaling: 1 fractional worksUbiquitin and proteasome pathways: 1 fractional worksPARP inhibition in cancer therapy: 1 fractional works
Radiology, Nuclear Medicine and ImagingOncologyMolecular BiologyPhysiology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 6 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 3 works
  3. 3 CAR-T cell therapy research Oncology 2 works
  4. 4 Peptidase Inhibition and Analysis Oncology 2 works
  5. 5 HER2/EGFR in Cancer Research Oncology 2 works
  6. 6 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 1 works
  7. 7 Epigenetics and DNA Methylation Molecular Biology 1 works
  8. 8 Adenosine and Purinergic Signaling Physiology 1 works
  9. 9 Ubiquitin and proteasome pathways Molecular Biology 1 works
  10. 10 PARP inhibition in cancer therapy Oncology 1 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available33.4%not open66.6%

World: 28% of research is openly available.

with international co-authors15.2%domestic only84.8%

World: 19% is written across borders.

How has Jiangsu T-mab BioPharma (China)'s research output changed?

Output in 2018–2022 was 675% higher than in 2013–2017.

20152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Taizhou

All research institutions in Taizhou

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.